


Edited by Jean-Marc Cavaillon
and Mervyn Singer

Inflammation

From Molecular and Cellular Mechanisms
to the Clinic

Volume 1,2,3 and 4



Edited by
Jean-Marc Cavaillon and
Mervyn Singer

Inflammation

Inflammation

From Molecular and Cellular Mechanisms to the Clinic

Edited by Jean-Marc Cavaillon and Mervyn Singer

WILEY-VCH
Verlag GmbH & Co. KGaA

Editors

Professor Dr. Jean-Marc Cavaillon
Institut Pasteur
Unit Cytokines & Inflammation
rue Dr. Roux 28
75015 Paris
France

Professor Dr. Mervyn Singer
University College London
Bloomsbury Institute of Intensive
Care Medicine
Cruciform Building
Gower St
WC1E 6BT London
United Kingdom

■ All books published by **Wiley-VCH** are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.:
applied for

British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library.

**Bibliographic information published by
the Deutsche Nationalbibliothek**
The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <http://dnb.d-nb.de>.

© 2018 Wiley-VCH Verlag GmbH & Co. KGaA,
Boschstr. 12, 69469 Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Print ISBN: 978-3-527-33899-3
ePDF ISBN: 978-3-527-69218-7
ePub ISBN: 978-3-527-69216-3
Mobi ISBN: 978-3-527-69217-0
oBook ISBN: 978-3-527-69215-6

Typesetting Thomson Digital, Noida, India

Printing and Binding

Printed on acid-free paper

10 9 8 7 6 5 4 3 2 1

Table of Contents

Preface *xlv*

Volume I

1	Inflammation through the Ages: A Historical Perspective	1
	<i>Jean-Marc Cavaillon</i>	
1.1	Introduction	1
1.2	The First Treatments	1
1.3	The Definitions	3
1.4	Fever	3
1.5	Phagocytosis	4
1.6	Diapedesis	6
1.7	Chemotactism	7
1.8	Infection and Inflammation	8
1.9	Usefulness of Inflammation for Adaptive Immune Response	9
1.10	Mediators of Inflammation	10
	References	12

Part One Inducers and Sensors of Inflammation **17**

2	Pathogen-associated Molecular Patterns	19
	<i>Jean-Marc Cavaillon</i>	
2.1	Definition	19
2.2	Endotoxin	20
	2.2.1 Brief Historical Background	20
	2.2.2 Biochemical Characteristics	21
	2.2.3 Detection	23
	2.2.4 Natural Ligands	24
	2.2.5 Cell Activation	25
	2.2.6 Tolerance	26
2.3	Other Bacterial PAMPs	26
	2.3.1 Lipoproteins	26
	2.3.2 Lipoteichoic Acid	27
	2.3.3 Flagellin	28

2.3.4	Peptidoglycan	28
2.3.5	Fimbriae	30
2.3.6	Glycogolipids	30
2.3.7	Heat Shock Proteins	30
2.3.8	Bacterial DNA	31
2.3.9	Bacterial RNA	32
2.4	Viral PAMPs	33
2.5	Parasitic PAMPs	35
2.6	Fungal PAMPs	36
2.7	Synergy	37
	References	38
3	Damage-associated Molecular Patterns	57
	<i>Jean-Marc Cavaillon</i>	
3.1	Definition	57
3.2	Necrosis versus Apoptosis	58
3.3	Receptors of Danger Signals	58
3.4	Main DAMPs	60
3.4.1	High-mobility Group Box 1	60
3.4.2	Heat Shock Protein	61
3.4.3	RNA and DNA	62
3.4.4	Mitochondria	62
3.4.5	Histones	62
3.4.6	Uric Acid Crystals	63
3.4.7	ATP	63
3.4.8	S100A8/S100A9	64
3.4.9	Interleukin-1 α and Interleukin-33	64
3.4.10	Heme	65
3.4.11	Hyaluronan	65
3.4.12	Biglycan	66
3.4.13	Heparan Sulfate	66
3.4.14	Eosinophil-derived Neurotoxin	66
3.4.15	Peroxiredoxins	67
	References	67
4	Bacterial Toxins	81
	<i>Marina de Bernard and Cesare Montecucco</i>	
4.1	Introduction	81
4.2	Toxins Modulating the Activity of Inflammatory Caspases and Inflammasomes	82
4.3	Toxins Modulating the Intracellular cAMP Levels	84
4.4	Toxins Modulating MAPK Signaling	85
4.4.1	Synergy between ET and LT	86
4.5	Toxins Affecting Host Cell Motility	87
4.6	Toxins Blocking Protein Synthesis or Protein Folding	88
4.7	Conclusions	89
	References	90

5	Venoms	99
	<i>Catarina Teixeira, Vanessa Moreira, and José María Gutiérrez</i>	
5.1	Introduction	99
5.2	Inflammation Induced by Snake Venoms	100
5.3	Inflammation Induced by Scorpion Venoms	105
5.4	Inflammation Induced by Spider Venoms	107
5.5	Inflammation Induced by Venoms of Bees, Vespids, and Ants	110
5.6	Conclusions	112
	References	113
6	Hypoxia as an Inducer of Inflammation	129
	<i>Ariel Brandwein and Clifford S. Deutschman</i>	
6.1	Introduction	129
6.2	Oxygen Sensing	130
6.3	Mitochondrial Oxygen Sensing	131
6.4	The Role of Transcription Factors	132
	6.4.1 Hypoxia-Inducible Factor	133
	6.4.2 Nuclear Factor κ B	135
6.5	The Warburg Effect	135
6.6	Acute versus Chronic Hypoxia	136
6.7	Inflammasome Activation	137
6.8	Summary and Conclusions	139
	References	139
7	Vaccine Adjuvants	143
	<i>Dennis M. Klinman and Hidekazu Shirota</i>	
7.1	Introduction	143
7.2	Adjuvants Approved for Human Use	144
7.3	Aluminum Compounds: The Gold Standard	144
7.4	AS04	145
7.5	Calcium Phosphate	145
7.6	Emulsions	146
	7.6.1 IFA and CFA	146
	7.6.2 MF59	146
	7.6.3 AS03	147
7.7	Nano/microparticles Including Liposomes and Virosomes	148
7.8	Immune Stimulating Complexes	148
7.9	Cytokines	149
	7.9.1 IL-12	149
	7.9.2 IL-2	149
	7.9.3 IL-15	150
	7.9.4 GM-CSF	150
7.10	Adjuvants that Target Toll-like Receptors	150
	7.10.1 Introduction	150
	7.10.2 TLR2	151
	7.10.2.1 Overview	151
	7.10.2.2 TLR2 ligands	151

7.10.2.3	Clinical Activity	151
7.10.2.4	Safety	152
7.10.3	TLR3	152
7.10.3.1	Overview	152
7.10.3.2	TLR3 Ligands and Their Immunogenicity	152
7.10.3.3	Safety	153
7.10.4	TLR4	153
7.10.4.1	Overview	153
7.10.4.2	TLR4 Ligands	153
7.10.4.3	Clinical Activity	153
7.10.4.4	Safety	154
7.10.5	TLR5	154
7.10.5.1	Overview	154
7.10.6	TLR7/8	154
7.10.6.1	Overview	154
7.10.6.2	TLR7/8 Ligands and Their Preclinical Activity	155
7.10.6.3	Clinical Activity	155
7.10.6.4	Safety	155
7.10.7	TLR9	156
7.10.7.1	Overview	156
7.10.7.2	TLR9 Ligands	156
7.10.7.3	Clinical Activity	156
7.10.7.4	Safety	157
7.11	Adjuvant Combinations	157
7.12	Future Directions	157
	References	158
8	Pattern Recognition Receptors	175
	<i>Lauren Whitehead and Gordon D. Brown</i>	
8.1	Introduction	175
8.2	Toll-like Receptors	176
8.2.1	Cell Surface-bound TLRs	177
8.2.2	Endosomal TLRs	178
8.2.3	TLR Signaling	179
8.2.4	MyD88-dependent Signaling Pathway	179
8.2.5	TRIF Signaling Pathway	179
8.3	C-type Lectin Receptors	181
8.3.1	DC-SIGN	181
8.3.2	Mannose Receptor	182
8.3.3	Surfactant Protein D	182
8.4	Natural Killer Gene Complex-associated CLRs	183
8.4.1	Activation Receptors	183
8.4.2	Inhibitory Receptors	185
8.4.3	CLR Signaling	186
8.5	RIG-1-like Receptors	187
8.5.1	RLR Signaling	188
8.6	NOD-like Receptors	189

8.6.1	NOD1 and NOD2	191
8.6.2	NOD1 and NOD2 Signaling	192
8.6.3	NLRC4	192
8.6.4	NLRPs	192
8.7	DNA-sensing Molecules	193
8.7.1	Signaling Components of DNA-sensing Molecules	194
8.7.2	Cross-talk between PRRs	195
8.8	Conclusions	195
	Acknowledgments	196
	References	196

Part Two Inflammatory Cells 217

9	Monocytes and Macrophages	219
	<i>Irina N. Shalova, Shilpi Saha, and Subhra K. Biswas</i>	
9.1	Introduction	219
9.2	Origin and Differentiation	219
9.3	Activation and Polarization	221
9.4	Functions	222
9.4.1	Cytokine Production and Inflammation	223
9.4.2	Phagocytosis	224
9.4.3	Antigen Presentation	226
9.4.4	Migration	227
9.4.5	Immunoregulation	228
9.4.6	Vascular Functions	229
9.5	Molecular Pathways and Mechanisms Regulating Response	230
9.5.1	Signaling Pathways	230
9.5.2	Epigenetic Regulation	232
9.5.3	Micro-RNAs	234
9.6	Conclusions	235
	Acknowledgment	235
	References	236
10	Neutrophils	253
	<i>Salvatore Cuzzocrea</i>	
10.1	Characteristics	253
10.2	Hematopoiesis	254
10.3	Adhesion and Migration	255
10.3.1	Traffic and Margination	255
10.3.2	Adhesion to the Endothelial Wall	256
10.3.3	Transendothelial Migration	257
10.4	Phagocytosis and Degranulation	258
10.4.1	Phagocytosis	258
10.4.2	Degranulation	259
10.5	Cytokine Synthesis	260
10.5.1	TNF- α	260

10.5.2	IL-1 and IL-1 Receptor Antagonist	260
10.5.3	IL-8 as a Model of Chemokines	261
10.5.4	Modulation of Cytokine Expression and Production by Neutrophils	261
10.6	Neutrophil Apoptosis	261
10.7	Neutrophils in Pathology	262
10.7.1	Bacterial Infection	263
10.7.2	Tissue Injury-induced Inflammation: Ischemia-reperfusion Injury	263
10.7.3	Crystal-induced Inflammation	263
10.7.4	Cytokine-induced Inflammation: Rheumatoid Arthritis	263
10.7.5	Autoimmunity Against Neutrophil Components: Antineutrophil Cytoplasmic Antibodies and Vasculitis	264
10.7.6	Genetic Disorders of Neutrophil Regulations: Hereditary Periodic Fever Syndromes	264
10.7.7	Cystic Fibrosis: Neutrophil-mediated Tissue Damage and Concomitant Persistence of Infection	265
10.8	Conclusions	265
	References	266
11	Mast Cells: Master Drivers of Immune Responses against Pathogens	273
	<i>W.X. Gladys Ang and Soman N. Abraham</i>	
11.1	Introduction	273
11.2	Biology of Mast Cells	273
11.3	Role of Mast Cells in Immune Surveillance	275
11.3.1	Strategic Peripheral Location	275
11.3.2	Direct Recognition of Pathogens	275
11.3.3	Indirect Recognition of Pathogens	276
11.3.4	Activation by Endogenous Danger Signals	276
11.3.5	Degranulation and Secretory Responses to Pathogens	277
11.4	Mast Cells in Innate Immunity	278
11.4.1	Direct Bactericidal Activity of Mast Cells	278
11.4.2	Resistance to Exo- and Endotoxins	278
11.4.3	Induction of Immune Cell Trafficking to Sites of Infection	279
11.5	Mast Cells in Adaptive Immunity	279
11.5.1	Mast Cells as Effectors of Adaptive Immunity	279
11.5.2	Recruitment of DCs and Effector T Cells to Sites of Infection	280
11.5.3	Recruitment of Dendritic Cells and T Cells to Draining Lymph Nodes	280
11.5.4	Antigen Presentation	280
11.6	Enhancement of Immunity by Boosting Mast Cell Activity	281
11.6.1	Mast Cell Activators as Novel Vaccine Adjuvants	281
11.6.2	Synthetic Mast Cell Granules	281

11.7	Potentially Detrimental Roles of Mast Cell Activation during Immune Responses	282
11.7.1	Overactivation of Mast Cells	282
11.7.2	Negative Modulation of Immunity by Mast Cells	283
11.8	Concluding Remarks	283
	Acknowledgments	284
	References	284
12	Dendritic Cells in Inflammatory Disease	289
	<i>Bart N. Lambrecht, Martin Guillems, and Hamida Hammad</i>	
12.1	What Defines a Dendritic Cell?	289
12.2	Dendritic Cell Subsets	290
12.3	Dendritic Cells and T-cell Polarization	291
12.4	Dendritic Cells in Allergic Inflammation	292
12.4.1	Dendritic Cells are Necessary and Sufficient for Induction of Th2 Immunity	292
12.4.2	Different Subtypes of DCs Induce Th2 Immunity	293
12.4.3	Dendritic Cells are Also Required for Effector Th2 Immune Responses to Allergens	294
12.4.4	DCs Get Activated Directly after Exposure to Allergen	295
12.4.5	Lung DCs Activated Indirectly by Epithelial Cells	296
12.5	Inflammatory DCs' Role in Human Allergy	298
12.6	Dendritic Cells in Autoimmune Inflammatory Disease	298
12.7	Conclusions	299
	References	300
13	Roles for NK Cells and ILC1 in Inflammation and Infection	315
	<i>Christian A.J. Vosshehrich and James P. Di Santo</i>	
13.1	Introduction	315
13.2	Distinguishing Group 1 ILC and NK Cells	316
13.3	NK Cell and ILC1 Activating and Inhibitory Receptors	317
13.3.1	Natural Cytotoxicity Receptors	317
13.3.2	NKG2D	318
13.3.3	DNAX Accessory Molecule-1 (DNAM-1, CD226)	318
13.3.4	MHC Class I-specific Receptors and NK Cell "Education"	318
13.3.5	Are ILC1s "Educated" Similar to Conventional NK Cells?	319
13.4	Evidence for Distinct Subsets of NK Cells and ILC1	319
13.5	Effector Functions of NK Cells and ILC1	320
13.6	NK Cells and Group 1 ILCs in Inflammation and Infection	322
13.6.1	Mouse Cytomegalovirus	322
13.6.2	Influenza Virus	323
13.6.3	NK Cells and Other Viral Infections	324
13.6.4	Salmonella	324
13.6.5	Listeria monocytogenes	325
13.6.6	Mycobacteria and Other Bacteria	325
13.7	NK Cell and ILC1 Memory	326

13.8	Concluding Remarks: NK and ILC1 as Partners in a Type 1 Network	327
	References	329

14 Group 2 and 3 Innate Lymphoid Cells: New Actors in Immunity and Inflammation 341

Nicolas Serafini and James P. Di Santo

14.1	ILCs: A New Family of Innate Effector Cells	341
14.2	ILC2 and ILC3 Heterogeneity and Homeostasis	342
14.3	ILC2 in Acute and Chronic Inflammation	345
14.4	ILC3 in Acute and Chronic Inflammation	348
14.5	Therapeutically Harnessing ILC2 and ILC3	351
14.6	Concluding Remarks	352
	References	353

15 Th9 Cells: From the Bench to the Bedside and Back Again 365

Benjamin J. Ulrich, Matthew M. Hufford, and Mark H. Kaplan

15.1	The History of T Helper Cells	365
15.2	Introduction to Th9 Cells	367
15.2.1	Development	367
15.2.2	Additional Th9-inducing Cytokines	368
15.2.3	Th9-inducing Cell Surface Ligands	369
15.2.4	The Function of Th9 Cells	369
15.3	Th9 Cells in Disease: The Helpful and Unhelpful	371
15.3.1	Tumor Immunity	372
15.3.2	Helminth Immunity	372
15.3.3	Inflammatory Bowel Disease	373
15.3.4	Allergic Inflammation	374
15.3.5	Dermatitis	376
15.3.6	Food Allergy	377
15.4	Targeting Th9 Cells Therapeutically	377
15.4.1	Th9 Differentiation	377
15.4.1.1	Cytokines and Costimulators Required for Differentiation	377
15.4.1.2	Transcription Factors for Differentiation	379
15.4.1.3	Factors Required for Promotion of Th9 Biology	380
15.4.2	Th9-associated Effector Molecules	381
15.5	Summary and Future Directions	382
	References	382

16 Th17 Cells 395

Mélissa Noack and Pierre Miossec

16.1	Introduction	395
16.2	Differentiation of Th17 Cells	396
16.2.1	Th17 Cell Differentiation in Mice	396
16.2.2	Th17 Cell Differentiation in Humans	397
16.2.3	Pathogenic Th17 Cells	398

16.2.4	Circulating versus Tissue Phenotypes	398
16.3	Cytokines and Chemokines Related to Th17 Cells	399
16.3.1	Major Cytokines and Chemokines Produced by Th17 Cells	399
16.3.1.1	IL-17A (IL-17)/IL-17F	399
16.3.1.2	IL-21	400
16.3.1.3	IL-22	400
16.3.1.4	CCL20	400
16.3.2	Major Cytokines Acting on Th17 Cells	401
16.3.2.1	IL-23	401
16.3.2.2	IL-27	401
16.4	Th17 and Inflammatory Diseases	401
16.4.1	Psoriasis	402
16.4.2	Arthritic Diseases	402
16.4.3	Multiple Sclerosis	403
16.4.4	Inflammatory Bowel Diseases	403
16.5	Mechanisms in Chronic Inflammation	403
16.5.1	Differentiation, Recruitment, and Maintenance of Th17 Phenotype during Chronic Inflammation	403
16.5.2	Secretion of IL-17 and its Activity	404
16.6	Plasticity of Th17 Cells	405
16.7	Clinical Targeting of Th17 Cells	407
16.8	Conclusions	408
	Acknowledgment	408
	References	408
17	Platelets	419
	<i>Jack Levin</i>	
17.1	Introduction	419
17.2	Expression of Toll-like Receptors	422
17.3	Interactions between Platelets and Bacteria	422
17.4	Interactions between Platelets and White Blood Cells	423
17.5	Platelet Integrins	424
17.6	Role of Platelets in Immune Responses	425
17.7	Platelets and Inflammatory Disorders	425
17.8	Malaria	426
17.9	Systemic Lupus Erythematosus	426
17.10	Conclusions	426
	References	427
18	Epithelial Cells	437
	<i>Jill M. Hoffman and Charalabos Pothoulakis</i>	
18.1	Introduction	437
18.2	The Intestinal Epithelium: An Archetypal Epithelial Barrier	438
18.3	Choosing a Cell Fate: The Absorptive Lineage	438
18.4	Choosing a Cell Fate: The Secretory Lineage	439
18.4.1	Goblet Cells	439

18.4.2	Paneth Cells	441
18.4.3	Enteroendocrine Cells	441
18.5	The Epithelium: The Sum is Greater than its Parts	442
18.6	Epithelial Homeostasis: Maintaining the Balance	443
18.6.1	Wnt Signaling	443
18.6.2	Notch Signaling	444
18.6.3	Inflammation-induced Alterations in Epithelial Cells	445
18.7	Concluding Remarks	447
	References	447

19	Inflammation: The Role of Endothelial Cells	457
	<i>J. Steven Alexander, D. Neil Granger, and Norman R. Harris</i>	
19.1	Introduction	457
19.2	Vasomotor Dysfunction	458
19.2.1	Mechanism of Vascular Smooth Muscle Contraction/relaxation	459
19.2.2	Endothelial Cell-dependent Vasoactivity	459
19.2.3	Endothelium-dependent Vasoactivity in IBD	460
19.2.3.1	Leukocyte- and Platelet-endothelial Cell Adhesion	461
19.2.3.2	Enhanced Thrombosis	463
19.2.3.3	Angiogenesis/vasculogenesis	465
19.2.3.4	Junctional and Vascular Permeability	468
19.3	Conclusions	470
	References	471

Volume II

Part Three Inflammatory Mediators 477

20	IL-1 Superfamily and Inflammasome	479
	<i>Charles A. Dinarello</i>	
20.1	Introduction	479
20.1.1	The IL-1 Family of Cytokines and the Innate Immune System	479
20.1.2	The Family of IL-1 of Receptors	481
20.1.3	The IL-1 Family Consensus Sequence	481
20.1.4	The IL-1 Family as Therapeutics	482
20.2	IL-1 α	483
20.2.1	Historical Background	483
20.2.2	Systemic Effects of IL-1 α in Humans	483
20.2.3	IL-1 α is a Dual-function Cytokine	484
20.3	Cell Sources, Production, and Secretion	484
20.3.1	Large Amounts of Constitutive IL-1 α in Healthy and Disease Cells	484
20.3.2	IL-1 α as a Growth Factor	485
20.3.3	Membrane IL-1 α	485
20.3.4	Studies in IL-1 α -deficient Mice	486

20.4	IL-1 β	486
20.4.1	Historical Background	486
20.5	Systemic Effects of IL-1 β in Humans	487
20.5.1	Transcription, Translation, and Synthesis of IL-1 β	487
20.5.2	Regulation of IL-1 β Production	487
20.5.3	The NLRP3 Inflammasome-dependent Processing and Secretion of IL-1 β	488
20.5.4	P2X7 and the Activation of the Inflammasome	489
20.5.5	Noncaspase-1 Processing of IL-1 β	489
20.5.6	Effects in Mice Deficient in IL-1 β	490
20.6	IL-18 and IL-18-binding Protein	490
20.6.1	Processing of the IL-18 Precursor by Caspase-1	491
20.6.2	Signal Transduction by IL-18	491
20.6.3	Role of IL-18 in the Production of IFN γ	492
20.6.4	IL-18, IL-17, and Gamma/delta T-Cell Activation	492
20.7	IL-18 and Inflammation	493
20.7.1	Proinflammatory Properties of IL-18	493
20.7.2	IL-18 in Heart Disease	494
20.8	IL-18 as a Protective Cytokine	495
20.9	IL-18-binding Protein	495
20.9.1	Background on IL-18BP	495
20.9.2	The Concept of Free IL-18	496
20.9.3	Regulation of IL-18BP	496
20.9.4	Viral IL-18BP	497
20.9.5	Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome	497
20.9.6	IL-18 in the Hemophagocytic Syndromes	497
20.10	IL-33	498
20.10.1	The Discovery of IL-33	498
20.10.2	Processing of IL-33	498
20.10.3	IL-33 Shares with IL-1 the Coreceptor IL-1R3	499
20.10.4	Nuclear Function of IL-33	499
20.10.5	Role of IL-33 in Human Disease	500
20.11	IL-36	500
20.11.1	IL-36 Background	500
20.11.2	Role of IL-36 in Disease	500
20.12	IL-37	501
20.12.1	Background of IL-37	501
20.12.2	The IL-37 Signaling Complex: Requirement for IL-1R5 and IL-1R8	501
20.12.3	Binding Studies	502
20.12.4	The IL-37, IL-18R α , and IL-1R8 Complex	502
20.12.5	Production of IL-37	503
20.12.6	Processing and Release	503
20.12.7	Effects of Recombinant IL-37	504
20.13	Disease Models in <i>IL37</i> -tg Mice	504
20.13.1	IL37-tg Mice	504

20.13.2	Experimental Colitis	505
20.13.3	Ischemic and Damage Models	505
20.13.4	Spinal Cord Injury	505
20.13.5	Metabolic Syndrome	505
20.13.6	Aging in IL37-tg Mice	506
20.13.7	Translocation of IL-37 to the Nucleus	506
20.13.8	Requirement for Smad3	507
20.13.9	A Role for IL-37 in Human Disease	507
20.14	IL-38	508
20.14.1	The Functional Role of IL-1 Family Member 10, Recently Renamed IL-38	508
	References	509

21	TNF Superfamily	529
	<i>Salvatore Cuzzocrea</i>	
21.1	Introduction	529
21.2	TNF α	530
21.3	TNF α : Biological Roles	530
21.4	Mechanisms of Action	531
21.5	Characterization of the TNF α Gene and Molecule	532
21.6	TNF Receptors and the TNF Receptor Superfamily	532
21.6.1	TL1A	533
21.6.2	FasL	534
21.6.3	LIGHT	534
21.6.4	DcR3	535
21.6.5	TRAIL	535
21.6.6	TWEAK	535
21.6.7	BAFF-R-BAFF	536
21.6.8	OX40-OX40L	536
21.6.9	GITR-GITRL	537
21.7	TNF Family: Role on Inflammatory Bowel Diseases	537
21.8	Role in Neuronal Inflammation	538
21.9	Conclusions	540
	References	541

22	Interleukin-17 A-E	549
	<i>Giovanni Monteleone, Irene Marafini, and Edoardo Troncone</i>	
22.1	Introduction	549
22.2	Cell Sources of IL-17 Cytokines	549
22.3	IL-17 Receptor: Structure and Biology	550
22.4	Production and Role of IL-17 Cytokines in Normal and Inflamed Intestine	551
22.5	IL-17 Blockers are Not Therapeutic in CD	553
22.6	IL-17 Cytokines in Psoriasis	553
22.7	Anti-IL-17 Therapy in Psoriasis	554
22.8	IL-17A in Psoriatic Arthritis	555
22.9	IL-17A in Rheumatoid Arthritis	556
22.10	Clinical Findings	556

22.11	IL-17B, IL-17C, and IL-17D	557
22.12	IL-25 (IL-17E)	557
22.13	Conclusions	559
	References	559
23	IL-6 Superfamily	573
	<i>Toshio Tanaka, Masashi Narazaki, and Tadamistu Kishimoto</i>	
23.1	Introduction	573
23.2	IL-6 and its Family of Cytokines	573
23.2.1	Biological Activity and Signaling System of IL-6	573
23.2.2	Original Members of IL-6 Family of Cytokines	575
23.2.3	New Members of IL-6 Family of Cytokines	575
23.2.4	Receptor Components of IL-6 Family of Cytokines	575
23.2.5	Soluble Forms of Receptors of IL-6 Family of Cytokines	577
23.2.6	Redundant and Nonredundant Functions of IL-6 Family of Cytokines	578
23.3	Clinical Application of Members of IL-6 Family of Cytokines and Their Inhibitors	578
23.3.1	Clinical Application of Members of IL-6 Family of Cytokines	578
23.3.2	Clinical Application of Inhibitors of Members of IL-6 Family of Cytokines	579
23.3.3	Present Status and Prospects of IL-6 Blockade Therapy	579
23.4	Concluding Remarks	582
	References	582
24	Type I and II Cytokine Superfamilies in Inflammatory Responses	587
	<i>William F. Carson IV and Steven L. Kunkel</i>	
24.1	Introduction	587
24.2	Cytokine–Receptor Interactions	588
24.3	Cytokine Superfamilies	589
24.3.1	Type I Superfamily	589
24.3.2	Common Gamma Chain	589
24.3.2.1	IL-2	590
24.3.2.2	IL-4	590
24.3.2.3	IL-7	591
24.3.2.4	IL-9	591
24.3.2.5	IL-15	592
24.3.2.6	IL-21	592
24.3.3	Common Beta Chain	592
24.3.3.1	IL-3	593
24.3.3.2	IL-5	593
24.3.3.3	GM-CSF	594
24.3.4	IL-12 Subfamily	594
24.3.4.1	IL-12	594
24.3.4.2	IL-23	595
24.3.4.3	IL-27	595
24.3.4.4	IL-35	596

24.3.5	Orphan Type I Cytokines	596
24.3.5.1	IL-13	597
24.3.5.2	IL-14	597
24.3.5.3	IL-32	597
24.3.5.4	IL-34	597
24.3.5.5	G-CSF	598
24.3.5.6	M-CSF	598
24.3.6	Type II Superfamily	598
24.3.7	Interferons	599
24.3.7.1	Type I: IFN- α , - β , and Variants	599
24.3.7.2	Type II: IFN γ	600
24.3.7.3	Type III: IFN λ -1, -2, and -3	600
24.3.8	IL-10 Subfamily	600
24.3.8.1	IL-10	601
24.3.8.2	IL-19	601
24.3.8.3	IL-20	602
24.3.8.4	IL-22	602
24.3.8.5	IL-24	602
24.3.8.6	IL-26	603
24.4	Summary: Cytokine Networks in Cellular Immunity	603
	References	604
25	Chemokines and Chemotaxis	619
	<i>Osamu Yoshie and Kouji Matsushima</i>	
25.1	Introduction	619
25.2	Chemokine and Chemokine Receptor Nomenclature Systems	626
25.3	Extravasation of Leukocytes: The Multistep Model	626
25.4	Inflammatory Chemokines and Homeostatic Chemokines	627
25.5	The Structure of Chemokines	630
25.6	Chemokine Receptors	632
25.7	The Two-step Model of Chemokine Receptor Activation	633
25.8	Signal Transduction	634
25.9	Atypical Chemokine Receptors	635
25.10	Organ Development and Chemokines	636
25.11	The Primary Lymphoid Organs and Chemokines	636
25.12	The Secondary Lymphoid Organs and Chemokines	637
25.13	Memory/effector T Cells and Chemokine Receptors	639
25.14	Mucosal Immunity and Chemokines	640
25.15	Skin Immunity and Chemokines	641
25.16	Clinical Applications	642
	References	643
26	Lipid Mediators in Inflammation	651
	<i>Shuh Narumiya, Takehiko Yokomizo, and Junken Aoki</i>	
26.1	Introduction: Biosynthesis, Degradation, and Receptors of Lipid Mediators	651
26.2	PGs in Inflammation	654

26.2.1	PGs in Acute Inflammation	654
26.2.2	PGs in Chronic Inflammation	657
26.2.2.1	PGs Act as Cytokine Amplifiers and Form Positive Feedback Loops of Inflammation Through Induction of COX-2	657
26.2.2.2	PGs in Autoimmune and Allergic Inflammation	659
26.2.2.3	PGs in Th1/Th17-mediated Autoimmune Inflammation	660
26.2.2.4	PGs in Th2-mediated Allergic Inflammation	661
26.2.2.5	PGs in Tissue Remodeling (Fibrosis, Angiogenesis, Lymphangiogenesis, etc.)	663
26.2.3	Anti-inflammatory Actions of PGs	663
26.3	LTs in Inflammation	664
26.3.1	LT Receptors	664
26.3.2	LTB ₄ and BLT1 in Acute and Chronic Inflammation	664
26.3.3	Roles of BLT2 in Inflammation and Tissue Homeostasis	665
26.3.4	CysLTs in Acute and Chronic Inflammation	666
26.3.5	Lysophospholipid, Lysophosphatidic Acid, and Sphingosine 1-Phosphate	667
26.3.6	Receptor for LPA and S1P	668
26.3.6.1	Receptors for LPA	668
26.3.6.2	Receptor for S1P	671
26.3.7	Synthetic Pathways and Enzymes for LPA and S1P	671
26.3.7.1	Synthetic Pathways and Enzymes for LPA	671
26.3.7.2	Synthetic Pathways for S1P	673
26.3.8	Degradation Pathway for LPA and S1P	674
26.3.9	Pathophysiological Roles of LPA and S1P in Inflammation	674
26.3.9.1	Role of LPA and S1P in Angiogenesis	674
26.3.9.2	Fibrosis	675
26.3.9.3	Neuropathic Pain	676
26.3.9.4	Roles of S1P and LPA in Lymphocyte Circulation	676
26.4	Concluding Remarks	677
	References	677
27	Free Radicals in Inflammation	695
	<i>Andrew Cumpstey and Martin Feelisch</i>	
27.1	Introduction	695
27.2	What Are Free Radicals?	696
27.3	Oxidative Stress and the Redox Code	697
27.4	Free Radical Production: The Mitochondrion	699
27.5	Reactive Oxygen Species	700
27.5.1	Superoxide	700
27.5.2	Hydrogen Peroxide, Hydroxyl Radical, and Oxidative Damage	701
27.6	Reactive Nitrogen Species	702

27.6.1	Nitric Oxide	702
27.6.2	Enzymatic and Nonenzymatic Production of Nitric Oxide	703
27.6.3	Nitrogen Dioxide, Peroxynitrite, and RNS Metabolism	704
27.6.4	RNS as Anti-infectious Agents	705
27.7	Reactive Sulfur Species	706
27.7.1	Thiyl and Other Sulfur-Based Radicals	706
27.7.2	Hydrogen Sulfide	707
27.7.3	Could RSS have been Mistaken for ROS?	708
27.8	Making Redox Regulation Work: ROS, RNS, and RSS Acting in Concert at the Level of Thiols	709
27.9	Antioxidants/Free Radical Scavengers	710
27.9.1	Dietary Antioxidants	710
27.9.2	Endogenous Antioxidants	711
27.9.3	Cells Respond to Oxidative Stress through Increased Antioxidant Gene Expression	712
27.9.4	Antioxidants: Harmful or Beneficial?	712
27.10	The Redox Code in Health and Disease	713
27.10.1	Inflammation and the Innate Immune Response	713
27.10.2	Aging	713
27.10.3	Diabetes Mellitus	714
27.10.4	Cardiovascular Disease: Atherosclerosis	715
27.10.5	Ischemia Reperfusion Injury	715
27.11	Looking to the Future: Newly Discovered Signaling Roles, the Reactive Species Interactome, and an Increasing Need to Assess the Role of Free Radicals in Personalized Medicine	716
27.11.1	Prognostic Markers in an Increasingly Personalized World of Medicine	717
27.11.2	The Reactive Species Interactome	717
27.12	Conclusions: Free Radicals, the Reactive Species Interactome, and Its Importance to the Inflammatory Response	718
	References	719
28	Proteases	727
	<i>Celine Deraison, Chrystelle Bonnard, and Nathalie Vergnolle</i>	
28.1	Introduction	727
28.2	Host Proteases and Inhibitors: Origin and Distribution	727
28.2.1	Inflammatory Cells	728
28.2.2	Resident Cells	728
28.2.3	Protease Inhibitors	729
28.3	Host Protease's Functions in Inflammation	731
28.3.1	Antimicrobial Functions	732
28.3.2	Inflammatory Mediator Processing	732
28.3.3	Junction Molecule Degradation	733
28.3.4	Mucus and Surfactant Protein Cleavage	734
28.3.5	Immunoglobulin Cleavage	734
28.3.6	Immunoproteasome, Antigen Presentation, and Processing	735

28.3.7	Matrix Remodeling	736
28.3.8	Receptor Activation	736
28.3.9	Apoptosis or Anoikis	738
28.3.10	Coagulation and Fibrinolysis	739
28.3.11	Kinin–Kallikrein System	740
28.3.12	Complement System Activation	741
28.3.13	Inflammasome	742
28.4	Microbial Proteases and Inflammation	742
28.4.1	Effects on Barrier Function	744
28.4.2	Effects on Vascular Permeability	745
28.4.3	Effects on Complement Proteins	746
28.4.4	Effects on Cytokine/Chemokine Production	746
28.5	Proteases as Targets in Inflammatory Pathologies	747
28.5.1	Gut	747
28.5.2	Airways	748
28.5.3	Skin	750
28.5.4	Joints	751
28.5.5	Pancreatitis	752
28.5.6	Traumatic Brain Injury	752
28.6	Conclusions	753
	List of Abbreviations	754
	Acknowledgments	755
	References	755
29	Psychiatric Disorders and Inflammation	767
	<i>Robert Dantzer</i>	
29.1	Introduction	767
29.2	Association Studies between Inflammation and Psychiatric Disorders	768
29.3	Mechanisms of the Association between Inflammation and Psychiatric Disorders	770
29.4	Other Causal Factors for the Relationship between Inflammation and Psychiatric Disorders	774
29.5	Relations between Inflammation and Neuropathology	775
29.6	Conclusions	776
	Acknowledgments	777
	References	777
30	Complement System	785
	<i>Peter A. Ward and Claudia Kemper</i>	
30.1	Introduction	785
30.2	Pathways of Complement Activation	785
30.2.1	Complement Activation	785
30.2.2	Complement Regulation	787
30.3	Activation Products of Complement	787
30.4	Receptors for Complement Activation Products	788
30.4.1	Opsonin Receptors	788

30.4.2	Anaphylatoxin Receptors	789
30.5	Role of Complement in Innate and Adaptive Immunity	790
30.5.1	Complement, Innate Immunity, and Acute Inflammation	790
30.5.2	Complement, Adaptive Immunity, and Chronic Inflammation	792
30.5.2.1	Humoral Immunity	792
30.5.2.2	T-cell Immunity	792
30.6	Evidence for Intracellular Activation of Complement	793
30.7	Roles of C5a, C5aRs, and C3aR in Inflammatory Disorders	795
30.7.1	Acute Respiratory Distress Syndrome (ARDS)	795
30.7.2	Sepsis	795
30.7.3	Acute Lung Injury	796
30.7.4	Biological Roles of C3a and C5a Receptors	798
30.8	Role of Complement in Selected Human Diseases	799
30.8.1	Vasculitis	799
30.8.2	Examples of Complement-related Glomerulopathies in Humans	799
30.8.2.1	Membranous Glomerulonephritis	799
30.8.2.2	C3 Glomerulonephritis	799
30.8.2.3	Hemolytic Uremic Syndrome and Related Disorders	801
30.8.2.4	Systemic Lupus Erythematosus and Lupus Nephritis	802
30.9	Strategies to Block Complement Activation and Complement Activation Products	802
30.9.1	Compstatin	802
30.9.2	C1 Esterase Inhibitor	802
30.9.3	C5 Blocking Antibodies	803
30.9.4	C5a Antibodies	803
30.10	Conclusions for Role of C3aR and C5aR	804
	Acknowledgments	804
	References	804

31 Heat Shock Proteins 813

Willem van Eden, Femke Broere, and Ruurd van der Zee

31.1	The Molecules (HSP Families)	813
31.2	Biological Function of HSPs (Chaperones)	813
31.2.1	The Markers of Cellular Stress	813
31.2.2	Molecular Basis of the Heat Shock Response	814
31.2.3	Triggers for the Heat Shock Response	815
31.2.4	The Chaperone Functions of HSP Families	816
31.2.5	HSP70 as a Prominent Peptide Donor for the MHCII Ligandome	817
31.3	The Immunology of HSPs	817
31.3.1	Immunodominance of Prokaryotic HSP	817
31.3.2	Cross-reactivity with Self-HSP	818
31.4	HSPs Protect in Models of Inflammatory Disease	819

31.5	HSP as Inflammatory Mediators	821
31.5.1	HSP are DAMPs?	821
31.6	HSP are DAMPERs of Inflammation	821
31.6.1	Effects of HSP on Mediators of Inflammation	822
31.6.2	HSP are Targets for a Default Regulatory Immune Response	822
31.6.3	HSP and Tregs	823
31.6.4	HSP Coinducing Substances	823
31.7	The Clinical use of HSP in Chronic Inflammatory Diseases	824
31.7.1	HSP Peptides and Proteins	824
31.7.2	TolDC Loaded with HSP Peptides	824
	References	825

Volume III

Part Four Inflammation and Host Response 831

32	Inflammation and Coagulation	833
	<i>Marcel Levi MD PhD</i>	
32.1	Introduction	833
32.2	Incidence of Inflammation-associated Coagulopathy	833
32.3	Clinical Relevance of the Interaction between Inflammation and Coagulation	834
32.4	Pathogenetic Pathways in the Coagulopathy of Sepsis	835
32.4.1	Initiation of Inflammation-induced Activation of Coagulation	835
32.4.2	Role of Platelets in Inflammation-induced Coagulation	836
32.4.3	Downregulation of Physiological Anticoagulant and Fibrinolytic Pathways during Inflammation	837
32.4.4	Antithrombin and Inflammation	837
32.4.5	Activated Protein C and Inflammation	838
32.4.6	Thrombomodulin and Inflammation	840
32.4.7	TFPI and Inflammation	841
32.5	Modulation of Inflammation by Coagulation <i>in vivo</i>	841
32.5.1	Extracellular DNA, Histones, and Neutrophil Extracellular Traps	842
32.6	Injured Endothelium and Microparticles	843
32.7	Systemic versus Localized Responses	843
32.8	Organ-specific Responses by Endothelial Cells	844
32.9	Diagnostic Approach to the Inflammation-induced Coagulopathy	845
32.10	Supportive Treatment of Coagulation Abnormalities during Severe Inflammation	847
	References	849
33	Fever: Mediators and Mechanisms	861
	<i>Joachim Roth</i>	
33.1	Introduction	861

33.2	Fever: Physiological and Neuroanatomical Considerations	862
33.2.1	Fever Defined	862
33.2.2	Possible Sites of Action for Putative Pyrogens within the Neuronal Thermoregulatory Circuitries	864
33.2.3	Experimentally Induced Fever	866
33.3	Putative Peripherally Generated Endogenous Pyrogens	868
33.3.1	The Classical Pyrogenic Cytokines: TNF- α , IL-1 β , and IL-6	868
33.3.2	Putative Peripheral Triggers for the Early Phase of Experimental Fever: PGE2, Complement Fragment C5a, or Oxygen Radicals	869
33.4	Transfer of Fever-generating Signals Across the Blood–Brain Barrier	870
33.4.1	Sensory Circumventricular Organs (Cvos)	871
33.4.2	Cells Forming the Blood–Brain Barrier	871
33.4.3	A Rapid Signal Transfer from the Periphery to the Brain via Sensory Nerves	873
33.4.3.1	The Afferent Vagus	873
33.4.3.2	Afferent Neuronal Signals from Other Nerves	873
33.5	Centrally Acting Pyrogenic Mediators and Processing of Febrile Signals in the Brain	874
33.5.1	The Role of PGE2 in the MnPO	874
33.5.2	The Role of Noradrenaline in the POA	874
33.5.3	Other Centrally Acting Endogenous Pyrogens (Cytokines, Chemokines, and Other Substances)	875
33.6	Clinical Aspects of Fever	875
33.6.1	Is Fever Beneficial or Harmful? Some Classical Arguments	876
33.6.2	Is Fever Beneficial or Harmful? No Clear Response from Clinical Studies	877
33.7	Concluding Remarks	878
	List of Abbreviations	878
	References	879
34	Pain	891
	<i>Christoph Stein</i>	
34.1	Introduction	891
34.2	Basic Concepts of Pain	891
34.2.1	Excitatory Mechanisms	892
34.2.2	Inhibitory Mechanisms	895
34.2.2.1	Opioid Receptors and Signaling	896
34.2.2.2	Plasticity of Opioid Receptors and Signaling Pathways	896
34.2.2.3	Endogenous Opioid Receptor Ligands	898
34.3	Clinical Concepts of Pain	899
34.3.1	Biopsychosocial Concept and Multidisciplinary Management	900

- cell surface-bound TLRs 177
- endosomal TLRs 178
- humans TLR4 expression 1153
- ligands 145, 296, 479, 602, 916
- MyD88-dependent signaling
 - pathway 179
- signaling 601
 - pathway 1370, 1371
- signaling pathway 180
- TLR signaling 179
- TLR2 34, 58, 151, 1426, 1474
 - mediated cell activation 34
 - stimulation 1264
- TLR3 152, 153
 - ligands/immunogenicity 152
 - dependent signaling 1264
- TLR4 153
 - deficient mice 64
 - inhibitors 1320
 - MyD88 signaling pathway 105, 1353
- TLR5 154
- TLR 7/8 154, 155
 - tolerizes cells 1426
- TLR9 156, 157
 - agonist CpG ODN 147
 - clinical activity 156
 - ligands 156
 - safety 157
 - transfected HEK cells 31
- TRIF signaling pathway 179
- vaccine adjuvants targeting
 - clinical activity 151, 153, 155
 - innate immune system 150
 - safety 152–155
- toxins blocking protein synthesis 88
- Toxoplasma gondii* 36, 178, 768, 1426
- TOX protein 342
- traditional Chinese medicine (TCM) 1661
- transcription activators 532, 921
- transcription factors 315, 341, 366, 395, 1315
- transforming growth factor (TGF) 262, 549, 734, 1328, 1385
 - TGF β 467, 676, 1368
 - activated kinase 179, 1385, 1430
 - TGF β /BMP signaling 1121
- transgenic mice expressing human IL-37 (IL37-tg) 501
- transient receptor potential V1 (TRPV1) 668
- transit-amplifying cell (TAC) 438
- transmembrane activator calcium modulator 536
- transplantation 1203
 - modulating inflammation to improve 1163
- treatment 1162
 - azathioprine 1162
 - CTLA4-Ig 1163
 - cyclosporine A 1162
 - monoclonal antibodies 1163
- Δ 10-trans-RvD2 isomer 1456
- transsulfuration pathway 707
- traumatic brain injury 1150
- Treg. *see* regulatory T cells (Treg)
- trehalose dimycolate (TDM) 185
- triacylated lipopeptide 25
- Trichuris muris* 345, 558
- trigeminal nerve 864
- triggering receptor expressed on myeloid cells-1 (TREM-1) 38, 1548, 1591
 - upregulated expression 1548
- triglycerides 1207, 1227
- trimethylamine-*N*-oxide (TMAO) 1288
- trinitrobenzene sulfonic acid (TNBS) 552, 661
 - induced colitis 494
- Tripterygium wilfordii* 1677
- Tripterygium wilfordii* Hook F 1674
- TRX interacting protein (TXNIP) 138
- Trypanosoma cruzi* 550
 - infections 35
- trypanosomatidae DNAs 62
- TSH administration 916
- T suppressor cells 1377
- tuberous sclerosis complex (TSC) 1381
- tubular cell apoptosis 1307
- tubulin 818
- tubulointerstitial fibrosis (TIF) 676

- tumor
 - antigen MAGE-3 157
 - associated macrophages 229
 - immunity 372
 - progression 220
 - regression 235, 1394
 - tumor necrosis factor (TNF) 21, 103, 109, 274, 397, 530, 732, 768, 791, 834, 837, 862, 1000, 1096, 1176, 1199, 1330, 1425, 1428, 1519, 1543
 - biological roles 530
 - converting enzyme (TACE) 34, 530
 - gene 1330
 - molecule, characterization of 532
 - IFN- γ 1228
 - immunoblockade 465
 - induced gene expression 658
 - mechanisms of action 531
 - promoter 1338
 - related apoptosis-inducing ligand receptor 1371
 - role in neuronal inflammation 538
 - role on inflammatory bowel diseases 537
 - signaling 1590
 - soluble 530
 - superfamily
 - actions of 531
 - members 540
 - synthesis 1520
 - tumor necrosis factor receptor (TNFR) 529, 530, 532, 1385
 - associated factor 550
 - interactions 538
 - superfamily 529, 532
 - BAFF-R-BAFF 536
 - DcR3 535
 - Fas ligands 534
 - GITRL 537
 - OX40 or ACT35 or CD134 or TNFRSF4 536
 - TL1A 533
 - TRAIL 535
 - TWEAK 535
 - TNFR-1 531
 - TNFR-associated death domain (TRADD) 529
 - TNFR-associated factor (TRAF) 1371, 1430
 - TNFRSF interactions 538
 - TNFRSF1B encoding receptor 1331
 - TxA2. *see* thromboxane A2 (TxA2)
 - typhoid vaccine 4
 - tyrosine 186
 - autophosphorylation 1231
 - phosphorylation 1230, 1231
- U**
- ubiquitin E3 ligase 822
 - ulcerative colitis (UC) 374, 400, 457, 460, 537, 540, 1336
 - ultrasound 1573
 - ultraviolet and/or ionizing radiation 696
 - uncoupling proteins 699
 - unfolded protein response (UPR) 89
 - unilateral ureteral obstruction (UUO) 675
 - uric acid 185, 711
 - ustekinumab 352, 407, 555
 - uveitis 499
 - UV-inactivated virus 11
 - UV-treated fibroblasts 63
- V**
- vaccination
 - with HSP60-derived peptide p227 824
 - immunogenicity 143
 - against tumor antigens 1394
 - target toll-like receptors 150
 - clinical activity 151, 153, 155
 - innate immune system 150
 - safety 152–155, 157
 - TLR2 151
 - TLR3 ligands/immunogenicity 152
 - TLR4 153
 - TLR5 154
 - TLR7/8 154, 155
 - TLR 9 156

- vaccinia virus (VV) 317
 - vagus nerve 864
 - stimulation (VNS) 1491
 - valine 46 503
 - vascular adhesion protein 1 792, 1578
 - vascular cell adhesion molecule 1 (VCAM-1) 1207, 1474
 - vascular disease, in type 2 diabetes 1234
 - vascular endothelial (VE)
 - cadherin (cadherin-5) 469
 - vascular endothelial growth factor (VEGF) 109, 220, 274, 465, 657, 1118, 1428
 - depleting antibodies 465
 - proteolytic modification 466
 - receptor 466
 - receptor 2 468
 - activity 467
 - VEGF-A isoforms 466
 - VEGF-A-mediated angiogenic signaling 468
 - VEGF/VEGFR complexes 466
 - vascularization 636
 - vasculitis 792, 799, 802, 1567, 1575
 - detected by [^{18}F]FDG PET/CT 1576
 - lesions of 799
 - vasoactive intestinal peptide (VIP) 1496
 - vasodilation 112
 - vasomotor dysfunction 458–460
 - angiogenesis/vasculogenesis 465
 - endothelial cell-dependent
 - vasoactivity 459
 - endothelium-dependent vasoactivity
 - in IBD 460
 - enhanced thrombosis 463
 - junctional 468
 - leukocyte–endothelial cell
 - adhesion 461
 - vascular smooth muscle contraction/relaxation 459
 - VEGF. *see* vascular endothelial growth factor (VEGF)
 - venom-induced inflammation 99
 - venomous animals 99
 - scorpions 105
 - venous congestion 1308
 - ventilator-associated pneumonia (VAP) 1335
 - vesicular stomatitis virus (VSV) 34
 - vespids
 - inflammation induced by
 - venoms 110–111
 - venoms 111
 - vessel wall inflammation,
 - chronic 792
 - Vibrio cholerae* 83
 - vaccine 146
 - Viperidae family 100
 - viral IL-6 575
 - viral IL-18BP, natural
 - neutralization 497
 - viral infections 1395, 1398
 - virosomes, nano/microparticles 148
 - virtual screening 1676
 - virulence factors 1584
 - virus-associated inflammatory PD
 - models 1260
 - virus-induced
 - immunopathology 1396
 - visceral adipose tissue (VAT) 322, 1389
 - endothelial cells 1205
 - visceral epithelial cell (VEC) 800
 - visceral fat 1226
 - visfatin 926
 - vitamin A deficiency 347
 - vitamin C (ascorbic acid) 710
 - vitamin D 347
 - vitamin D3 (1,25-dihydroxyvitamin D3) 825
 - vitamin K deficiency 846
 - von Hippel–Lindau protein (VHL) 134
 - tumor suppressor gene 134
 - von Willebrand factor 836, 845, 1154
 - cleaving protease 837
- W**
- Warburg effect 135, 1383
 - warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome 636

- Waterhouse-Friderichsen syndrome 833
 - WEHI164 clone 532
 - Weibel-Palade storage granules 1154
 - West Nile virus (WNV) 317
 - white adipose tissue (WAT) 922
 - mast cells 1204
 - Willebrand factor 836
 - multimers 1595
 - Willow tree 1672
 - Wnt agonist R-spondin-1 444
 - Wnt/beta-catenin 1212
 - signaling pathway 538
 - Wnt inhibitory factor (WIF) 444
 - Wnt-receptor complex 443
 - Wnt signaling 444
 - pathway 438
 - wound healing, resolution of 1455
 - WSXWS amino acid motif 598
- X**
- xanthine oxidase 700, 716, 976, 1314
 - XIAP gene mutations 497
 - Xigris 796
- Y**
- yellow fever virus 33
- Z**
- zeta chain-associated protein kinase 70
 - (Zap70) deficiency 1065
 - zinc metalloproteinase (Zmp) 957
 - zonula occludens (ZO) 469, 733
 - zymosan-induced peritonitis 1498